|
Title
|
Publication Date
|
Price
|
Relevance
|
|
IMS Company Profiles: Lundbeck
|
Oct 2010 |
£640 |
100% |
|
H. Lundbeck A/S: PharmaVitae Model
|
Jan 2009 |
£3,605 |
99% |
|
H. Lundbeck A/S-Detailed Product Pipeline
|
Mar 2011 |
£475 |
99% |
|
Lundbeck: Pipeline - Products - Performance - Potential
|
Jun 2010 |
£595 |
99% |
|
H. Lundbeck A/S-Therapeutic Competitors Report
|
Mar 2011 |
£220 |
99% |
|
H. Lundbeck A/S: PharmaVitae Profile
|
Jun 2010 |
£3,605 |
98% |
Partnering Agreements with LundBeck
2010
|
Jan 2010 |
£630 |
98% |
|
Lundbeck Inc. (formerly Ovation Pharmaceuticals, Inc.)-Therapeutic Competitors Report
|
Mar 2011 |
£220 |
98% |
|
H. Lundbeck A/S-Deals & Alliances Report
|
Mar 2011 |
£380 |
98% |
|
H Lundbeck AS - Financial and Strategic Analysis Review
|
Apr 2009 |
£79 |
98% |
|
Lundbeck Inc. (formerly Ovation Pharmaceuticals, Inc.)-Deals & Alliances Report
|
Mar 2011 |
£380 |
97% |
Key Companies: Depression - Leading players must adapt to remain competitive
Consumer
|
Aug 2011 |
£2,405 |
87% |
|
Huntington's Disease Therapeutics
|
Apr 2010 |
£2,500 |
86% |
R&D Trends: Depression
Pipeline characterized by its depth and diversity
|
Apr 2011 |
£2,405 |
84% |
|
The Pharmaceutical Market: Denmark
|
Oct 2011 |
£595 |
83% |
|
Sleeping Pills
|
Aug 2010 |
£2,500 |
83% |
Sareum Holdings plc – Product Pipeline Review
H2 2011
|
Nov 2011 |
£315 |
83% |
Product Profiles: Depression
Next generation vies for second-line patients
|
Jun 2011 |
£7,210 |
82% |
|
CNS Drug Discoveries: Neurodegenerative Disorders
|
Nov 2006 |
£795 |
81% |
|
The Outlook for Pharmaceuticals in Northern Europe
|
Nov 2011 |
£1,995 |
80% |
Acute Ischemic Stroke Therapeutics
Pipeline Assessment and Market Forecasts to 2017
|
Dec 2010 |
£1,265 |
79% |
Forecast Insight: Depression
High rewards for novel and adjunctive therapies in treatment-resistant depression
|
Dec 2010 |
£9,615 |
78% |
Schizophrenia
Pipeline Assessment and Market Forecast to 2017
|
Dec 2010 |
£1,265 |
78% |
|
Alzheimer's Disease Market analysis and forecasts, 2007-2012, 2017 & 2022
|
Oct 2007 |
£1,499 |
78% |
Lennox-Gastaut Syndrome Global Clinical Trials Review
Q1, 2011
|
Jan 2011 |
£630 |
76% |
Partnering Yearbook
2012
|
Jan 2012 |
£1,895 |
75% |
|
CNS Drug Discoveries: Alzheimer's Disease Chapter
|
Aug 2008 |
£595 |
75% |
Partnering Agreements with Bigpharma
3rd Edition
|
Oct 2010 |
£630 |
75% |
Friedreich Ataxia Global Clinical Trials Review
H1, 2012
|
Jan 2012 |
£630 |
75% |
Psychopharmacotherapy Market Insights
Obstacles & Opportunities in Mood Disorders & Cognitive Impairment, 2005-2012
|
Nov 2005 |
£795 |
75% |
